Skip to main content

Intelligent Pharma opens its second subsidiary office in Europe

By 11 de June de 2011November 18th, 2020No Comments
< Back to news

Intelligent Pharma opens its second subsidiary office in Europe

The biotech Intelligent Pharma —with headquarters at the Barcelona Scientific Park and specialized in the development, commercialization and use of new computational technologies for drug designs— has just opened a new subsidiary office in Hertfordshire, in the north of London (United Kingdom), just a year after the opening of its first international office in Heidelberg (Germany). This second European delegation is in BioPark Hertfordshire, a prosperous scientific community of biopharmaceutical and medical technology and specialized services suppliers.

“The opening of this new delegation in the United Kingdom is one step more in the internationalization of the company. Our spirit is to become a global company, and this is just one of the steps we have to take to reach this goal,” according to Dr. Ignasi Belda words. He is founder and managing director of Intelligent Pharma.

From 27th to 30th June, a company delegation will travel for fourth consecutive year to the main biotech world fair, BIO, with the Catalan delegation of companies (coordinated by Biocat). This year the trade show will be held in Washington, DC. The objective is to open a branch office in the United States.

Intelligent Pharma has managed, only with four years of life, to “have practically all Spanish pharmaceutical companies, a great number of biotechnological companies and public life sciences research institutions as customers,” as explains Dr Belda, and it has consolidated as referent in its area in Spain.

Regarding its international presence, it has a large client portfolio in the United Kingdom, United States and Mexico, and has established an agreement of collaboration with the British multinational IDBS. Last March, the company also signed its first two research contracts in the United States with SciClone Pharmaceuticals, specialized in drug development for the Chinese market in the areas of oncology and infections.